Practical tips, tricks and interpretation of IVUS and OCT images
Details
This session will focus on how to obtain optimal IVUS and OCT images as well as how to analyze and interpret them.
This program is made possible by an unrestricted educational grant from Abbott.
The technologies been discussed may not be approved for use in your country.
Organised by
Date
- America/New_York
Carlo Di Mario
Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the...
Read MoreCarlo Di Mario is Professor of Cardiology at the University of Florence and Director of the Structural Interventional Cardiology Division of the University Hospital Careggi, Florence, Italy. Previous posts included 15 years as Professor of Clinical Cardiology at Imperial College of Sciences, Medicine & Technology, London and Consultant Cardiologist at the Royal Brompton Hospital. Despite his teaching, research and administrative commitments, he maintains an active clinical involvement performing more than 100 PCI per year with special interest in the treatment of calcified lesions, chronic total occlusions, bifurcations, and diffuse disease. He is a regular TAVI operator and certified implanter for the Medtronic Evolut R and Edwards Sapien 3 transcatheter aortic valves. He participated in more than 160 MitraClip implantations in London and Florence and has recently started direct annuloplasty with the CardioBand. Professor Di Mario pioneered the use of intracoronary Doppler, pressure measurement, intravascular ultrasound, optical coherence tomography, and near infrared spectroscopy. He was PI of the OPTICUS trial, failing to demonstrate superiority of IVUS guided stenting, and of the Lipid Rich Plaque study, due to report at TCT 2018. He was Principal Investigator of the DESTINI trial, using Doppler CRF to identify lesions in need of stenting, and of the CARESS in AMI trial, a large multicentre trial showing that patients who receive fibrinolytic therapy for ST-elevation myocardial infarction benefit from early angioplasty. This trial and a subsequent meta-analysis have led to a change in the European Society of Cardiology and AHA/ACC Guidelines for treatment of STEMI patients. He cooperated with Dr Davies to the validation of iFR to assess lesion severity and discriminate the contribution of individual lesions, and with Dr Lyon in the intracoronary delivery of SERCA-2 genes via adenoviral vectors in the CUPID2 trial.
Show LessOzan Demir
Dr. Ozan Demir is a Structural and Interventional Cardiology Fellow at Hammersmith Hospital...
Read MoreDr. Ozan Demir is a Structural and Interventional Cardiology Fellow at Hammersmith Hospital London. He recently completed post as Clinical Research Fellow at St Thomas’ Hospital and King’s College London, where he is undertook a PhD in coronary physiology under the supervision of Professor Divaka Perera. He studied Medicine at King’s College London and trained in London prior to undertaking Interventional Cardiology Fellowships at Hammersmith Hospital, London and San Raffaele, Milano. During his Fellowship in Milano, under the supervision of Professor Antonio Colombo and Professor Azeem Latib, he undertook an MSc in Interventional Cardiology at the Università Vita-Salute San Raffaele. He is currently involved in various clinical research studies on cardiovascular physiology.
Show LessPaweł Gasior
Asst. Prof. Pawel Gasior is an interventional cardiology fellow in Division of Cardiology and...
Read MoreAsst. Prof. Pawel Gasior is an interventional cardiology fellow in Division of Cardiology and Structural Heart Diseases, Medical University of Silesia in Poland. He is a Fellow of the European Society of Cardiology and the currently act as co-chair of the EAPCI New Initiatives for Young Interventionalists Committee. Following graduation from Medical University of Silesia he undertook research fellowship at Cardiovascular Research Foundation in New York under supervision of Dr. Juan Granada. Besides clinical medicine, he is also engaged in both clinical and preclinical research on intravascular imaging, new intravascular technologies, coronary physiology and coronary artery disease.
Show Less